Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Schering-Plough discusses Pegintron trials

Schering-Plough discusses Pegintron trials

29th April 2009

Schering-Plough undertook three large clinical studies of Pegintron to help investigators address important clinical issues regarding patients with hepatitis C, it has asserted.

The company presented its findings of the trials at the 44th European Association for the Study of the Liver 2009 Annual Meeting.

By investigating the medication in over 2,700 sufferers, the aim of the studies was to evaluate developing regimens compared to the current standard practice.

Dr Robert J Spiegel, chief medical officer and senior vice-president of the business’ research institute, explained improved treatments of the disease to reduce side effects and improve tolerability in sufferers are always being sought.

“Conducting these studies demonstrates Schering-Plough’s longstanding commitment to investigating potential new treatment strategies for patients with hepatitis C,” he remarked.

Earlier this month, the company released its first quarter fiscal results of the year.

Chairman and chief executive of the firm Fred Hassan said a solid performance has been delivered, adding the business will continue to drive forward with the planned merger with Merck.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.